

Vivian Lui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/917972/publications.pdf>

Version: 2024-02-01

130
papers

7,095
citations

66343

42
h-index

62596

80
g-index

132
all docs

132
docs citations

132
times ranked

9590
citing authors

#	ARTICLE	IF	CITATIONS
1	Head and neck squamous cell carcinoma. Nature Reviews Disease Primers, 2020, 6, 92.	30.5	1,649
2	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. Cancer Discovery, 2013, 3, 761-769.	9.4	505
3	TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression. Cancer Research, 2012, 72, 3270-3281.	0.9	252
4	Exome and genome sequencing of nasopharynx cancer identifies NF- κ B pathway activating mutations. Nature Communications, 2017, 8, 14121.	12.8	227
5	STAT3 as a therapeutic target in head and neck cancer. Expert Opinion on Biological Therapy, 2006, 6, 231-241.	3.1	212
6	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncology, 2011, 7, 1149-1167.	2.4	191
7	Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2015, 126, 169-180.	8.2	156
8	Phosphorylation of TNF- α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6901-6906.	7.1	130
9	Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3473-82.	7.1	127
10	Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer, 2017, 17, 375.	2.6	125
11	Microneedle-Mediated Delivery of Lipid-Coated Cisplatin Nanoparticles for Efficient and Safe Cancer Therapy. ACS Applied Materials & Interfaces, 2018, 10, 33060-33069.	8.0	125
12	Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. Cancer Letters, 2014, 349, 15-25.	7.2	99
13	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection. Molecular Cancer Research, 2014, 12, 571-582.	3.4	94
14	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clinical Cancer Research, 2013, 19, 380-392.	7.0	90
15	Translational genomics of nasopharyngeal cancer. Seminars in Cancer Biology, 2020, 61, 84-100.	9.6	90
16	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1114-1119.	7.1	86
17	Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 541-551.	3.8	82
18	Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene, 2003, 22, 6183-6193.	5.9	78

#	ARTICLE	IF	CITATIONS
19	Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer, 2013, 13, 619.	2.6	76
20	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular Cancer Therapeutics, 2007, 6, 1414-1424.	4.1	73
21	Enhanced IL-6/IL-6R Signaling Promotes Growth and Malignant Properties in EBV-Infected Premalignant and Cancerous Nasopharyngeal Epithelial Cells. PLoS ONE, 2013, 8, e62284.	2.5	69
22	STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells <i>in vitro</i> . International Journal of Cancer, 2009, 125, 1884-1893.	5.1	67
23	Microneedles loaded with anti-PD-1 cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. Nanoscale, 2020, 12, 18885-18898.	5.6	67
24	Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and <i>in vivo</i> tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis, 2009, 30, 2085-2094.	2.8	66
25	Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting. Clinical Cancer Research, 2008, 14, 7682-7690.	7.0	65
26	Gastrin-Releasing Peptide Receptor-Mediated Autocrine Growth in Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute, 2002, 94, 375-383.	6.3	63
27	Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1. Molecular Pharmacology, 2007, 71, 1435-1443.	2.3	63
28	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. Journal of Clinical Oncology, 2009, 27, 1235-1242.	1.6	63
29	EGFR-mediated cell cycle regulation. Anticancer Research, 2002, 22, 1-11.	1.1	62
30	JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. Neoplasia, 2015, 17, 256-264.	5.3	59
31	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Investigational New Drugs, 2010, 28, 413-420.	2.6	58
32	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Investigational New Drugs, 2010, 28, 107-114.	2.6	56
33	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer, 2013, 13, 602.	2.6	56
34	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF- κ B activation and immune escape. Nature Communications, 2021, 12, 4193.	12.8	56
35	Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene, 2011, 30, 1127-1134.	5.9	55
36	Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells. Neoplasia, 2005, 7, 426-431.	5.3	51

#	ARTICLE	IF	CITATIONS
37	Targeting tumor hypoxia in nasopharyngeal carcinoma. Head and Neck, 2013, 35, 133-145.	2.0	51
38	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. PLoS ONE, 2015, 10, e0135750.	2.5	51
39	The Fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2013, 743-744, 78-88.	1.0	50
40	Cancers of the lung, head and neck on the rise: perspectives on the genotoxicity of air Pollution. Chinese Journal of Cancer, 2014, 33, 476-80.	4.9	50
41	Proteomic Characterization of Head and Neck Cancer Patientâ€Derived Xenografts. Molecular Cancer Research, 2016, 14, 278-286.	3.4	48
42	The <i>RARSâ€MAD1L1</i> Fusion Gene Induces Cancer Stem Cellâ€like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2018, 24, 659-673.	7.0	47
43	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2015, 1, 238.	7.1	44
44	Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer. Cancers, 2018, 10, 210.	3.7	43
45	Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma. Carcinogenesis, 2003, 24, 1705-1712.	2.8	41
46	Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis. Cancer Immunology, Immunotherapy, 2019, 68, 221-232.	4.2	41
47	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Investigational New Drugs, 2010, 28, 326-333.	2.6	40
48	KIAA0495/PDAM Is Frequently Downregulated in Oligodendroglial Tumors and Its Knockdown by siRNA Induces Cisplatin Resistance in Glioma Cells. Brain Pathology, 2010, 20, 1021-1032.	4.1	40
49	Prediction of radiotherapy response with a 5â€microRNA signatureâ€based nomogram in head and neck squamous cell carcinoma. Cancer Medicine, 2018, 7, 726-735.	2.8	40
50	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Investigational New Drugs, 2013, 31, 567-575.	2.6	38
51	JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against <i>MYCN</i>-amplified small cell lung cancer. Oncotarget, 2017, 8, 86312-86324.	1.8	37
52	A small molecule inhibitor of NF-Î²B, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Letters, 2010, 287, 23-32.	7.2	36
53	Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. Journal of Gene Medicine, 2001, 3, 384-393.	2.8	34
54	The Intersection between Oral Microbiota, Host Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 3425.	3.7	33

#	ARTICLE	IF	CITATIONS
55	Systemic Administration of Naked DNA Encoding Interleukin 12 for the Treatment of Human Papillomavirus DNA-Positive Tumor. <i>Human Gene Therapy</i> , 2002, 13, 177-185.	2.7	30
56	STAT3 as a therapeutic target for Epstein-Barr virus (EBV) -associated nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2013, 330, 141-149.	7.2	30
57	Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. <i>Cancer Letters</i> , 2014, 343, 24-32.	7.2	30
58	Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2003, 9, 5028-35.	7.0	30
59	FHL2 exhibits anti-proliferative and anti-apoptotic activities in liver cancer cells. <i>Cancer Letters</i> , 2011, 304, 97-106.	7.2	29
60	Specific Down-regulation of HER-2/neu Mediated by a Chimeric U6 Hammerhead Ribozyme Results in Growth Inhibition of Human Ovarian Carcinoma. <i>Molecular Therapy</i> , 2001, 3, 169-177.	8.2	28
61	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation. <i>Biochemical Pharmacology</i> , 2010, 79, 1772-1780.	4.4	28
62	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , 2011, 29, 1123-1131.	2.6	28
63	Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2012, 83, 1146-1158.	4.4	28
64	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. <i>Life Science Alliance</i> , 2020, 3, e201900545.	2.8	27
65	Quantitative Proteomics Analysis Reveals Molecular Networks Regulated by Epidermal Growth Factor Receptor Level in Head and Neck Cancer. <i>Journal of Proteome Research</i> , 2010, 9, 3073-3082.	3.7	26
66	TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells. <i>Oncology Letters</i> , 2015, 9, 569-574.	1.8	26
67	The cylindromatosis (CYLD) gene and head and neck tumorigenesis. <i>Cancers of the Head & Neck</i> , 2016, 1, 10.	6.2	23
68	Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. <i>Oncolmmunology</i> , 2018, 7, e1388484.	4.6	23
69	A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy. <i>Current Cancer Drug Targets</i> , 2015, 15, 327-336.	1.6	22
70	Precision drugging of the MAPK pathway in head and neck cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 20.	3.8	22
71	Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. <i>Investigational New Drugs</i> , 2011, 29, 401-410.	2.6	21
72	K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , 2012, 30, 48-58.	2.6	21

#	ARTICLE	IF	CITATIONS
73	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. <i>Biochemical Pharmacology</i> , 2010, 79, 842-852.	4.4	20
74	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013, 2013, 1-10.	1.1	20
75	Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , 2011, 29, 1241-1252.	2.6	17
76	Mesenchymal stem cells participate in oral mucosa carcinogenesis by regulating T cell proliferation. <i>Clinical Immunology</i> , 2019, 198, 46-53.	3.2	15
77	miR-466 is putative negative regulator of Coxsackie virus and Adenovirus Receptor. <i>FEBS Letters</i> , 2015, 589, 246-254.	2.8	14
78	Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 262.	8.6	13
79	Omics-wide quantitative B-cell infiltration analyses identify GPR18 for human cancer prognosis with superiority over CD20. <i>Communications Biology</i> , 2020, 3, 234.	4.4	13
80	Potential of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. <i>Gene Therapy</i> , 1998, 5, 1462-1471.	4.5	12
81	Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck. <i>Molecular Pharmacology</i> , 2008, 73, 627-638.	2.3	12
82	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1417-1425.	2.3	12
83	Hypermethylation of NF- κ B-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 676-686.	2.3	12
84	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 1107.	2.6	12
85	Emerging Roles of ALK in Immunity and Insights for Immunotherapy. <i>Cancers</i> , 2020, 12, 426.	3.7	12
86	Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 106486-106498.	1.8	12
87	FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation. <i>Oncogene</i> , 2011, 30, 1518-1530.	5.9	11
88	Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer. <i>Head and Neck Pathology</i> , 2012, 6, 91-97.	2.6	11
89	Effects of Salivary Mg on Head and Neck Carcinoma via TRPM7. <i>Journal of Dental Research</i> , 2019, 98, 304-312.	5.2	11
90	Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study. <i>EBioMedicine</i> , 2021, 65, 103242.	6.1	10

#	ARTICLE	IF	CITATIONS
91	Induction of laryngeal cancer cell death by Entinostat (hydroxyethyl xanthate) and cisplatin. <i>Head and Neck</i> , 2010, 32, 1506-1518.	2.0	9
92	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. <i>Investigational New Drugs</i> , 2013, 31, 30-38.	2.6	9
93	An update of ALK inhibitors in human clinical trials. <i>Future Oncology</i> , 2016, 12, 71-81.	2.4	9
94	Case Report: Exome sequencing reveals recurrent RETSAT mutations and a loss-of-function POLDIP2 mutation in a rare undifferentiated tongue sarcoma. <i>F1000Research</i> , 2018, 7, 499.	1.6	9
95	Andrographis paniculata elicits anti-invasion activities by suppressing TM4SF3 gene expression and by anoikis-sensitization in esophageal cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 3570-87.	1.4	9
96	Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma. <i>Npj Genomic Medicine</i> , 2020, 5, 17.	3.8	8
97	MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. <i>Oncotarget</i> , 2016, 7, 23300-23311.	1.8	8
98	Full-length Mst1 exhibits growth promoting function in human hepatocellular carcinoma cells. <i>FEBS Letters</i> , 2013, 587, 496-503.	2.8	7
99	Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey. <i>JCO Oncology Practice</i> , 2020, 16, e770-e778.	2.9	7
100	Identification of Mutations in the PYRIN-Containing NLR Genes (NLRP) in Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e85619.	2.5	6
101	Thrombomodulin (TM) in tumor cell differentiation and periphery blood immune microenvironment in oral squamous cell carcinoma. <i>Clinical Immunology</i> , 2018, 191, 27-33.	3.2	5
102	Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2019, 20, 52-64.	3.4	5
103	Combinations of proteasome inhibitors with obatociclib are effective for small cell lung cancer. <i>Acta Pharmacologica Sinica</i> , 2020, 42, 1298-1310.	6.1	5
104	Germline mutation and aberrant transcripts of <i>WWOX</i> in a syndrome with multiple primary tumors. <i>Journal of Pathology</i> , 2019, 249, 19-25.	4.5	4
105	Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes. <i>Cancers</i> , 2020, 12, 2935.	3.7	4
106	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. <i>PLoS ONE</i> , 2016, 11, e0166185.	2.5	4
107	An update on genomic-guided therapies for pediatric solid tumors. <i>Future Oncology</i> , 2017, 13, 1345-1358.	2.4	2
108	Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein-Barr virus in situ assays. <i>Cancer</i> , 2018, 124, 434-435.	4.1	2

#	ARTICLE	IF	CITATIONS
109	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines. Cancer Research, 2012, 72, 4602-4602.	0.9	2
110	Hong Kong releases Copyright (Amendment) Bill 2006. Computer Law and Security Review, 2006, 22, 418-420.	2.2	1
111	Abstract 1373: Preclinical activity of axitinib and its associated change of serum biomarkers in nasopharyngeal carcinoma (NPC). , 2012, , .		1
112	Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer.. , 2013, , .		1
113	Abstract 646: Targeting MHC class I molecules and immune checkpoints as key immune evasion strategies in EBV-associated nasopharyngeal carcinoma. , 2017, , .		1
114	Abstract 4033: RAC1 genomic aberrations as predictive biomarkers for head and neck squamous cell carcinoma (HNSCC). , 2019, , .		1
115	Abstract 2527: Genomic aberrations of <i>ALK</i> in head and neck squamous cell carcinoma. Cancer Research, 2019, 79, 2527-2527.	0.9	1
116	Correction: c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clinical Cancer Research, 2013, 19, 3715-3715.	7.0	0
117	Abstract 3088: Mammalian sterile-20 like kinase 1 (Mst1) upregulates cyclin D1 to promote hepatocellular carcinoma cell growth. , 2010, , .		0
118	Abstract 1006: TP53-induced glycolysis and apoptosis regulator (TIGAR) induces NADPH production and growth in nasopharyngeal carcinoma cells. , 2011, , .		0
119	Abstract 2811: Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. , 2012, , .		0
120	Abstract 2037: Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. , 2012, , .		0
121	Abstract 4668: Antitumor efficacy of AZD1480 in head and neck squamous cell carcinoma.. , 2013, , .		0
122	Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC.. , 2013, , .		0
123	Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCC. , 2014, , .		0
124	Abstract 5003: Functional significance of TIGAR expression in nasopharyngeal carcinoma. , 2014, , .		0
125	Abstract 5712: Potential clinical significance of downregulation of MAPK pathway components mRNA expression in head and neck squamous cell carcinoma (HNSCC). , 2017, , .		0
126	Abstract 4278: Somatic MAPK pathway mutations are associated with high mutational burden and good survival in head and neck squamous cell carcinoma (HNSCC). , 2018, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract 5347: Somatic mutation and overexpression of anaplastic lymphoma kinase (ALK) are uncommon events in Asian head and neck cancers. , 2018, , .		0
128	Abstract 4507: Study of CCCTC-binding factor (CTCF) genetic aberrations and dysregulation in head and neck squamous cell carcinoma (HNSCC). , 2019, , .		0
129	Abstract 4933: RAPTOR protein overexpression is predictive of poor clinical outcomes in head and neck squamous cell carcinoma (HNSCC) patients. , 2019, , .		0
130	Abstract 98: Stromal-targeting with quercetin in patient-derived models of head and neck squamous cell carcinoma (HNSCC). , 2019, , .		0